AGE-RELATED FEATURES OF THE DISTRIBUTION OF THE FREQUENCY OF OCCURRENCE OF LUMINAL A MOLECULAR-BIOLOGICAL SUBTYPE OF BREAST CANCER
E.A. Novikova ¹, V.Y. Krokholev ¹, O.V. Kostromina ¹, S.M. Demidov ¹,², S.V. Sazonov ¹,²
DOI: 10.22138/2500-0918-2021-18-1-35-42
¹ Ural State Medical University, Yekaterinburg, Russian Federation;
² Institute of Medical Cell Technologies, Yekaterinburg, Russian Federation
Abstract. Aim. In this article, we analyzed the age-related features of molecular- biological subtypes in 499 patients with invasive breast cancer. Materials and research methods. All cases were divided into 5 molecular- biological subtypes based on immunohistochemical studies of hormone receptors, Her2, Ki-67. Luminal (A and B) with the expression of estrogen and/or progesterone receptors (ER+/PR+), accounting for about 50-80% of all breast cancer cases and potentially sensitive, especially luminal A, to hormone therapy. Research results. The analysis showed that in our study the proportion of the Luminal A subtype was lower than the generally accepted values of 37.4% of all studied breast cancer cases. In the group of women under 40 years of age (with preserved menstrual-ovarian function), cases of Luminal A subtype were significantly less common (9.03%) compared to the groups of 41-50 years (p<0.006), 51-60 years (p<0.001), and over 60 (p<0.001). There was also a decrease in the proportion of Luminal A subtype among patients older than 60 years (p=0.0064). No significant differences were found between the groups 41-50 and over 60 years of age (p=0.1868).
Keywords: breast cancer, molecular-biological subtypes, Luminal A subtype, immunohistochemistry, age structure
There is no conflict of interest.
Contact details of the corresponding author:
Sergey V. Sazonov
prof-ssazonov@yandex.ru
Received 07.04.2021
For citation:
Novikova E.A., Krokholev V.Y., Kostromina O.V., Demidov S.M., Sazonov S.V. Age-Related Features of the Distribution of the Frequency of Occurrence of Luminal A Molecular-Biological Subtype of Breast Cancer [Online] Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2021, Vol. 18, no. 1, pp. 35–42. DOI: 10.22138/2500-0918-2021-18-1-35-42 (In Russ)
REFERENCES
1. Rahimzade S.Ye. Breast cancer: Epidemiology, Risk factors, Pathogenesis, Diagnosis, Prognosis. National Center of Oncology, Baku, Azerbaijan Republic, 2016. (In Russ.).
2. Zaridze D.G., Kaprin A.D., Stilidi I.S. Dynamics of morbidity and mortality from malignant neoplasms in Russia. Oncology issues, 2018, 5 (64), P. 578-591. (In Russ.).
3. Petrov S.V., Akhmetov T.R., Balatenko N.V., Mazitova F.M., Galliev M.V., Zagoskin D.O. Twenty years of routine immunohistochemical and molecular-cytogenetic diagnosis of tumors in Tatarstan: achievements and difficulties when used in clinical oncology, Povolzhsky Oncological Bulletin, 2016, No. 3, (25), S.52-58. (In Russ.).
4. Petkau V.V., Bulavina I.S., Sakaeva D.D., Strakhova N.V., Sazonov S.V. Age features of breast cancer. Ural Medical Journal, 2012, 4, (96), 24-26. (In Russ.).
5. Leonard R.C., Barrett-Lee P.J., Gosney M.A. et al. Effect of patient age on man agement decisions in breast cancer: consensus from anation al consultation. The Oncologist. 2010, 15, 657-664.
6. Yancik R., Wesley M.N., Ries L.A. et al. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. JAMA 2001, Vol. 285(7), 885- 892.
7. Leontiev S.L., Sazonov S.V. Creation of a system for reviewing immunohistochemical studies in the diagnosis of breast cancer. Bulletin of the Ural Medical Academic Science. [Vestnik Uralskoy medicinskoy akademicheskoy nauki [Vestnik Uralskoy medicinskoy akademicheskoy nauki], 2012, 1 (38), 18-22. (In Russ.).
8. Sazonov S.V., Leontiev S.L., Brilliant A.A. Experience of the reference laboratory for HER2 / Neu testing of breast carcinoma in the Sverdlovsk region. Bulletin of the Ural Medical Academic Science. [Vestnik Uralskoy medicinskoy akademicheskoy nauki], 2013, No. 1 (43), 56-60. (In Russ.).
9. Frank GA, Andreeva Yu.Yu., Vinogradov I.Yu., et al. 10 years of testing the HER2-status of breast cancer in Russia. Archive of pathology, 2012, Vol. 74, No. 5, 3-6. (In Russ.).
10. Novikova E.A., Kostromina O.V., Mikhailov D.V., Leontiev S.L., Sazonov S.V. Age features of molecular biological subtypes of breast cancer. Bulletin of the Ural Medical Academic Science. [Vestnik Uralskoy medicinskoy akademicheskoy nauki], 2020, 2 (17), 187-192. (In Russ.).
11. Wilcken N., Hornbuckle J., Ghersi D. Cochrane Database of Systematic Reviews. 2003, (83) 8, 411-417.
12. Diab S.G., Elledge R.M., Clark G. M. Tumor characteristics and clinical outcome of elderly women with breast cancer, 2000. 350 р.
13. Brilliant A.A., Brillant Yu.M., Sazonov S.V. Characteristics of the relation between epithelial-mesenchymal transition and proliferative activity in breast carcinomas. European Journal of Cancer. 2013, 49 (2), 216.
14. Novikova E.A., Kodintsev A.N., Sazonov S.V., et al. Expression of the enzyme topoisomerase-II alpha in molecular genetic subtypes of breast cancer. Bulletin of the Ural Medical Academic Science. [Vestnik Uralskoy medicinskoy akademicheskoy nauki], 2016, No. 4, 30–37. (In Russ.).
15. Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer, The Oncologist, 2004, 9, 606-616.
16. Kroger N., Milde-Langosch K., Riethdorf S. et al. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res, 2006, 12(1), 158-168.
17. Harutyunyan E.V., A.A. Brilliant, E.A. Novikova, S.V. Sazonov Some patterns of expression of immunohistochemical markers on breast carcinoma cells. Ural Medical Journal, 2014, 2 (116), 5-8. (In Russ.).
18. Goldhirsch A., Wood W.C., Coates A.S. et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen Internation al Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann. of Oncol., 2011, 22, 1736- 1747
19. Owens M.A., Horten B.C., Da Silva M.M. HER-2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues, Clin. Breast Cancer, 2004, 5, 63-69.
20. Wolff A.C., Hammond M.E.H., Schwartz J.N. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J. Clin. Oncol, 2007, № 25, 118–145.
21. Semiglazov V.F., Paltuev R.M., Manikhas A.G. and other. Clinical guidelines of the ROOM for the diagnosis and treatment of breast cancer. Clinical guidelines ROOM. St. Petersburg. Publishing house «ABV-press». 2015.504 p. (In Russ.).
Authors
Evgeniya A. Novikova
Ural State Medical University
Candidate of Biological Sciences, Senior Lecturer, Department of Histology, Cytology and Embryology
3 Repin st. Yekaterinburg Russian Federation 620014
novikova.evgeniya2014@yandex.ru
Vadim Ya. Krokhalev
Ural State Medical University
Associate Professor, Department of Medical Physics, Informatics and Mathematics
3 Repin st. Yekaterinburg Russian Federation 620014
vkrokhalev@yandex.ru
Olga V. Kostromina
Ural State Medical University
Senior Lecturer, Department of Histology, Cytology and Embryology
3 Repin st. Yekaterinburg Russian Federation 620014
lelya88.70@mail.ru
Sergei M. Demidov
Institute of Medical Cell Technologies
Leading Researcher, Doctor of Medical Sciences, Professor,
20a K. Marx st. Yekaterinburg Russian Federation 620026
Sergey V. Sazonov
Ural State Medical University
Department of Histology, Cytology and Embryology
MD, professor, chief of the department
3 Repin st. Yekaterinburg Russian Federation 620014
Institute of Medical Cell Technologies
Deputy Chief Physician for Science
20a K. Marx st. Yekaterinburg Russian Federation 620026
prof-ssazonov@yandex.ru
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)